Naptumomab estafenatox

Naptumomab estafenatox (ABR-217620) is a tumor targeting superantigen (TTS). Naptumomab estafenatox is a fusion protein containing an anti-5T4 antibody and a SEA/E-120 superantige. Naptumomab estafenatox can be used for the research of lung cancer[1].

Research Areas >> Cancer

Signaling Pathways >> Others >> Others

Naptumomab estafenatox (0.001-10000 pM；4 小时) 对人葡萄球菌肠毒素 A (SEA) 介导的 T 细胞对 Caki-2 和 Raji 细胞的 EC50 分别为 20 和 30000 pM[1]。 Naptumomab estafenatox (0.001-10000 pM；4 小时) 对 SEA/E-120 介导的 T 细胞对 Caki-2 和 Raji 细胞的 EC50 分别为 0.1 和 100000 pM[1]。 Naptumomab estafenatox (1 pM-1 μM；4 天) 剂量依赖性地诱导人淋巴细胞增殖[1]。 Cell Proliferation Assay[1] Cell Line: Human peripheral blood mononuclear cell (PBMC) line Concentration: 1 pM-1 μM Incubation Time: 4 days Result: Dose-dependently induced proliferation of human PBMCs but more concentrations were needed compared with SEAwt (C242Fab-SEA) and anatumomab mafenatox.

Naptumomab estafenatox (0.016 mg；静脉注射，每日 1 次，共 8 天) 对有 Calu-1 肿瘤的免疫缺陷小鼠具有抗肿瘤作用[1]。 Animal Model: SCID mice with Calu-1 tumors and PBMC injection[1] Dosage: 0.016 mg Administration: Intravenous injection, 0.016 mg, daily injection for 8 days Result: Significantly reduced the tumor mass.

[1]. Forsberg G, et al. Naptumomab estafenatox, an engineered antibody-superantigen fusion protein with low toxicity and reduced antigenicity. J Immunother. 2010 Jun;33(5):492-9.  

[2]. Elkord E, et al. Immunological response and overall survival in a subset of advanced renal cell carcinoma patients from a randomized phase 2/3 study of naptumomab estafenatox plus IFN-α versus IFN-α. Oncotarget. 2015 Feb 28;6(6):4428-39.